A comparative double-blind randomised study of single dose fosfomycin trometamol with trimethoprim in the treatment of urinary tract infections in general practice

Chemotherapy. 1990;36 Suppl 1:34-6. doi: 10.1159/000238814.

Abstract

A double-blind, double-dummy trial comparing a single dose treatment with fosfomycin trometamol (FT, 3 g) versus trimethoprim (TMP, 200 mg) was carried out in women with uncomplicated urinary tract infections. From 51 clinically evaluable patients, 44 were bacteriologically assessable at the 6-week follow-up. The results were as follows in the FT group (n = 22): eradication in 17 (77.3%); recurrence in 2 (9%); reinfection in 2 (9%), and persistence in 1 (4.5%). For the TMP group (n = 22) the results were: eradication in 12 (54.5%); recurrence in 1 (4.5%); reinfection in 1 (4.5%), and persistence in 8 (33.3%). There were no significant adverse events reported with either agent.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Double-Blind Method
  • Drug Administration Schedule
  • Family Practice
  • Female
  • Fosfomycin / administration & dosage*
  • Fosfomycin / therapeutic use
  • Humans
  • Trimethoprim / administration & dosage*
  • Trimethoprim / adverse effects
  • Trimethoprim / therapeutic use
  • Urinary Tract Infections / drug therapy*

Substances

  • Fosfomycin
  • Trimethoprim